A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was 'is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?' Altogether, over 219 papers were found, of which 16 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Radiofrequency ablation (RFA) and stereotactic ablative radiotherapy (SABR) offer a clear survival benefit compared with conventional radiotherapy in the treatment of early stage non-small cell lung cancer (NSCLC) in medically inoperable patients. Overall survival at 1 year (68.2-95% vs. 81-85.7%) and 3 years (36-87.5% vs. 42.7-56%) was similar between patients treated with RFA and SABR. However, 5-year survival was higher in SABR (47%) than RFA (20.1-27%). Local progression rates were lower in patients treated with SABR (3.5-14.5% vs. 23.7-43%). Both treatments were associated with complications. Pneumothorax (19.1-63%) was the most common complication following RFA. Fatigue (31-32.6%), pneumonitis (2.1-12.5%) and chest wall pain (3.1-12%) were common following SABR. Although tumours ≤5 cm in size can be effectively treated with RFA, results are better for tumours ≤3 cm. One study documented increased recurrence rates with larger tumours and advanced disease stage following RFA. Another study found increasing age, tumour size, previous systemic chemotherapy, previous external beam radiotherapy and emphysema increased the risk of toxicity following SABR and suggested that risk factors should be used to stratify patients. RFA can be performed in one session, whereas SABR is more effective if larger doses of radiation are given over two to three fractions. RFA is not recommended for centrally based tumours. Patients with small apical tumours, posteriorly positioned tumours, peripheral tumours and tumours close to the scapula where it may be difficult to position an active electrode are more optimally treated with SABR. Treatment for early stage inoperable NSCLC should be tailored to individual patients, and under certain circumstances, a combined approach may be beneficial.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
THREE-PART QUESTION
In [ patients with early stage medically inoperable non-small cell lung cancer], is [radio-frequency ablation] superior to [stereotactic ablative radiotherapy] treatment?
CLINICAL SCENARIO
You are at a conference hearing about the effectiveness of radiofrequency ablation (RFA) and stereotactic ablative radiotherapy (SABR) in patients with early stage medically inoperable nonsmall cell lung cancer (NSCLC). You have an 85-year old patient who has been diagnosed with Stage IA NSCLC and is not fit for surgery due to his extensive comorbidities. You decide to do a literature search. 
SEARCH OUTCOME
The search returned 219 papers. In addition, the references of relevant papers were searched. Sixteen papers provided the best evidence to answer the question. These are tabulated in Table 1 .
RESULTS
The effectiveness of RFA and SABR in the treatment of inoperable NSCLC is well documented. Huang et al. [2] reported a median progression-free-interval of 21.6 months following RFA. Overall survival at 1, 2 and 5 years was 68.2, 35.3 and 20.1%, respectively, and 23.7% patients developed local progression during follow-up. There was no significant difference in outcome for tumours <3 cm, while there was a significant difference in the risk of local progression in tumours >4 cm (P = 0.01). In another study [3] , 57% of primary lung tumours treated with RFA had no recurrence. The local recurrence rate was 38%, with increasing tumour size (P = 0.02) and disease stage (P = 0.007) significantly increasing its likelihood.
de Baère et al. [4] documented an 18-month survival rate of 71%, and a trend towards better efficacy for tumours <2 cm in diameter (P = 0.066). The respiratory function was not adversely affected when measured within 2 months of RFA treatment (P = 0.51); however, the long-term effects are unknown and the FDA have received reports of patient deaths associated with lung tumour ablation using RFA.
Lencioni et al. [5] achieved a technical success rate of 99% in performing RFA. 12.5% of patients with NSCLC showed incomplete response or progression of disease. The overall 2-year survival of patients with NSCLC was 48%. Hiraki et al. [6] observed a high local progression rate (35%) within a median of 9.0 months after the first session.
Pennathur et al. [7] documented a local progression in 42%, and the median time to progression was 27 months. The overall 2-year survival rate was 49% for primary lung cancers. Simon et al. [8] documented a significant difference in survival between patients with large (>3 cm) and small (≤3 cm) tumours (P < 0.002). Local recurrence was most common, suggesting that more aggressive RFA and adjuvant radiation may improve outcomes [9, 10] . Kashima et al. [9] concluded that puncture number (P < 0.02) and previous systemic chemotherapy (P < 0.05) were significant risk factors for aseptic pleuritis. Increasing age (P < 0.02) and previous external beam radiotherapy (P < 0.001) were significant risk factors for pneumonia, as were emphysema (P < 0.02) for lung abscess and pneumothorax requiring pleural sclerosis (P < 0.02), and serum platelet count (P < 0.002) and tumour size (P < 0.02) for bleeding. Zemlyak et al. [10] reported comparable survival rates following sublobar resections (87.1%) and ablative therapies (87.5%). SABR, a non-invasive technique, precisely delivers very high radiation doses in a short period of time. It is well tolerated in patients with extensive comorbidity with high local control rates and minimal toxicity, and results have been so promising that there are ongoing trials comparing SABR with surgery in operable patients. Lagerwaard et al. [11] observed local recurrences in only 3.5% of patients, which is much less than previously reported when using conventional radiotherapy in Stage I NSCLC. Haasbeek et al. [12] found no significant difference in overall survival between the older and younger patient cohorts (P = 0.18) following SABR; however, disease-free survival was slightly better in older patients (P = 0.04). Le et al. [13] reported an association between prior thoracic radiotherapy or chemotherapy and treatment-related toxicity.
On comparing outcomes between patients treated with biologic effective doses (BED) of ≥100 Gy and <100 Gy, Onishi et al. [14] found improved local control and survival rates with BED ≥100 Gy. They reported the most benefit in those with medically operable tumours, treated with BED ≥100 Gy.
Timmerman et al. [15] reported a 3-year local control rate of 97.6%, and an overall 3-year survival rate of 55.8%. Fakiris et al. [16] reported lower rates of toxicity after SABR in patients with peripheral tumours. However, there was no significant difference in survival between patients with peripheral and central tumours (P = 0.69). The 3-year local control (88.1%) was comparable to that following lobectomy. Another study [17] reported mainly grade 1-2 toxicities (83%), consisting of fatigue, musculoskeletal discomfort and radiation pneumonitis. Most cases resolved within 3-4 months of SABR. The authors concluded that patients with perihilar/central tumours had an 11-fold increased risk of experiencing severe toxicity compared with more peripheral locations. Tumours close to the left hemidiaphragm may also be very dangerous to treat with SABR due to their proximity to the stomach.
CLINICAL BOTTOM LINE
SABR is associated with higher 5-year survival rates compared with RFA and conventional radical radiotherapy (40-47% vs. 20.1-27 vs. 19%) [18] and local control rates up to 80-90% [19] are two to three times greater than conventional fractionated radiotherapy. This modality has a favourable toxicity profile in peripheral tumours measuring ≤5 cm. RFA can be performed in one session, whereas SABR is more effective if larger doses of radiation are split over two to three fractions. RFA is more difficult in central tumours but is being increasingly performed with increased operator experience and confidence. Both treatment modalities are associated with side-effects, and risk factors should be used to stratify patients. Overlapping ablations in the same sitting also improve the outcomes for larger tumours. In certain circumstances, a combined approach may be beneficial.
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